Ionis Delivers Positive Late-Stage Results for Two Partnered Drugs
IONS posts positive phase III results for two partnered drugs, with ulefnersen meeting its ALS endpoint and sefaxersen cutting proteinuria.
Zacks Investment Research9/23/2026Positive
IONS
Ionis Pharmaceuticals IncNASDAQHEALTHCAREBIOTECHNOLOGY
Key Statistics
Market Cap
$7.28B
P/E Ratio
—
EPS
$-3.47
Beta
0.42
52W High
$86.74
52W Low
$43.01
50-Day MA
$55.05
200-Day MA
$71.44
Dividend Yield
—
Profit Margin
-64.70%
Forward P/E
90.91
PEG Ratio
25.70
About Ionis Pharmaceuticals Inc
Ionis Pharmaceuticals, Inc. discovers and develops RNA-targeted therapies in the United States. The company is headquartered in Carlsbad, California.
Fundamentals
| Revenue (TTM) | $874.09M |
| Gross Profit (TTM) | $-60.60M |
| EBITDA | $-579.48M |
| Operating Margin | -38.20% |
| Return on Equity | -105.50% |
| Return on Assets | -12.40% |
| Revenue/Share (TTM) | $5.36 |
| Book Value | $2.65 |
| Price-to-Book | 16.60 |
| Price-to-Sales (TTM) | 8.33 |
| EV/Revenue | 9.8 |
| EV/EBITDA | 135.77 |
| Quarterly Earnings Growth (YoY) | -43.70% |
| Quarterly Revenue Growth (YoY) | -40.70% |
| Shares Outstanding | $166.18M |
| Float | $164.82M |
| % Insiders | 0.61% |
| % Institutions | 110.53% |
Historical Volatility
HV 10-Day
65.84%
HV 20-Day
50.52%
HV 30-Day
49.99%
HV 60-Day
72.77%
HV Rank
81.7%
Volatility is currently expanding
Analyst Ratings
Consensus ($83.64 target)
9
Strong Buy10
Buy5
HoldLatest News
Ionis and Roche Advance First RNA-Targeted Therapy for Autoimmune Kidney Disease
Ionis Pharmaceuticals Inc. (NASDAQ:IONS) and licensing partner Roche Holdings AG (OTC:RHHBY) on Wednesday shared prespecified interim outcomes from their ongoing Phase 3 IMAgINATION trial of investigational sefaxersen in adults diagnosed with primary IgA nephropathy (IgAN).
Benzinga9/23/2026Positive
Ionis announces positive interim data from partner Roche's Phase 3 IMAgINATION study in IgA nephropathy (IgAN)
CARLSBAD, Calif.--(BUSINESS WIRE)--Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) and partner Roche today announced positive prespecified interim results from the ongoing Phase 3 IMAgINATION study evaluating investigational sefaxersen in adults with primary IgA nephropathy (IgAN). The study met its primary endpoint with sefaxersen achieving statistically significant and clinically meaningful improvements in proteinuria reduction, compared to placebo at 37 weeks, as measured by 24-hour urine protein.
Business Wire9/23/2026Neutral
Otsuka, Ionis' experimental ALS drug meets main goal in late-stage study
Otsuka Pharmaceutical and Ionis Pharmaceuticals said on Tuesday their experimental drug met the main goal of a late-stage study in patients with a rare inherited form of amyotrophic lateral sclerosis, or ALS.
Reuters9/22/2026Positive
Otsuka Announces Transformative Phase 3 FUSION Results for Ulefnersen, Bringing the FUS-ALS Community Closer to a Potential Targeted Treatment
PRINCETON, N.J. & TOKYO--(BUSINESS WIRE)--Otsuka Pharmaceutical Development & Commercialization, Inc., Otsuka Pharmaceutical Co., Ltd. (Otsuka) and Ionis Pharmaceuticals, Inc. today announced positive topline results from the Phase 3 FUSION trial evaluating ulefnersen, an investigational RNA-targeted medicine, in people living with a genetic subtype of amyotrophic lateral sclerosis (ALS) known as FUS-ALS, caused by mutations in the fused in sarcoma (FUS) gene1. The study met its primary end.
Business Wire9/22/2026Neutral
Ionis Pharmaceuticals, Inc. (IONS) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
Ionis Pharmaceuticals, Inc. (IONS) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
Seeking Alpha9/16/2026Neutral
Ionis Pharmaceuticals, Inc. (IONS) Presents at Wells Fargo 21st Annual Healthcare Conference Transcript
Ionis Pharmaceuticals, Inc. (IONS) Presents at Wells Fargo 21st Annual Healthcare Conference Transcript
Seeking Alpha9/10/2026Neutral
Novartis' Del-desiran Fails Late-Stage DM1 Study, Shares Fall
NVS' del-desiran fails the HARBOR study's primary endpoint, adding to recent pipeline setbacks as investors await next steps.
Zacks Investment Research9/9/2026Negative
Novartis Late-Stage Cardiovascular Outcome Study Fails, Stock Down
Novartis' pelacarsen study failed to cut cardiovascular events, clouding prospects for the drug and highlighting portfolio challenges.
Zacks Investment Research9/7/2026Negative
Amgen Shares Fall as Novartis' Pelacarsen Misses Phase III Study Goal
AMGN shares fall as NVS' pelacarsen setback casts investor concern over whether olpasiran can deliver positive phase III outcome data.
Zacks Investment Research9/7/2026Negative
Turn research into an automated options-selling system
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on IONS and any ticker you trade — then tracks every position and per-strategy win rate.
More HEALTHCARE Stocks
Data last updated: 9/26/2026